Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction (Centre Daily Times)
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced the final two-year results for the Company’s trial evaluating Prochymal ® for the treatment of acute myocardial infarction. Prochymal is a proprietary formulation of adult stem cells designed to provide therapeutic benefit by controlling inflammation, promoting tissue regeneration, and preventing scar formation. This double-blind, …
[Read the full article here]Related News:
First Patient Treated In Osiris Phase II Stem Cell Trial For Heart Attacks
Osiris Therapeutics Reports Fourth Quarter and Full Year 2008 … – Phramalive.com
Osiris Therapeutics Announces Cardiac Stem Cell Therapy Presentation At BMT Tandem Meeting